Repligen (RGEN)
(Real Time Quote from BATS)
$167.12 USD
+0.07 (0.04%)
Updated May 6, 2024 12:42 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Repligen Corporation [RGEN]
Reports for Purchase
Showing records 161 - 180 ( 201 total )
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Top- and Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Financing Transactions Indicate Investor Demand; Long-Term Projections Improved; Upgrading to Buy With $110 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Record Revenue With Earnings Slightly Ahead of Projections; Raising Target to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
3Q18 Results Reported; Still an Expensive Stock; Reiterate Neutral and Raising Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Welsh Agarose Plant Opens on Schedule; Estimates Revised; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Pricey But Built to Last; Initiating at Neutral and $49 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 17This report contains brief updates on the following: PCYC, LGND, ONXX, RGEN, ANAC, ARNA, ONCY, CRDC. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Termination of Coverage
Provider: RODMAN & RENSHAW, CO.
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Termination of Coverage
Provider: RODMAN & RENSHAW, CO.
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Preliminary Results - Incorporating the Novozymes Acquisition
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Preliminary Results - Incorporating the Novozymes Acquisition
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E